Indian Pharma MNC goes digital to tackle lost market share
About the Industry Partner
Our Industry Partner is one of the premium branded generic pharmaceutical companies of India. With focus on almost all the major therapeutic areas, this report covers the challenge faced by them in the 3 molecules in the management of osteoporosis namely; Calcium, Vitamin D3 & Teriparatide.
Calcium & Vitamin D3 helps in meeting insufficient dietary requirements associated with osteoporosis.
Teriparatide, a biosimilar helps in building new bones in cases of severe osteoporosis.
Company was losing market share to its competitors for all the three molecules in both prescription & OTC markets.
We identified the following key concern areas.
(covered by sales team)
(not covered by sales team)
Identified Key Objectives
We went beyond “REACH”
HCP Sentiment Analysis
Unprejudiced social listening to understand trends around the brands, osteoporosis, available molecules & competitors
Contents designed as per HCP sentiments to bust myths & address concerns
Dynamic content strategy with focus changed to “Boosting immunity”, keeping it relevant to COVID-19 information
Spike in viewership & engagement of target HCPs across India
Innovative marketing collaterals
Innovative GIF flyers for both online and offline promotion of our partner’s infocenter to HCPs
Maximize reach & engagement of target audience even in tier 2 & tier 3 cities
with minimum investment
An exclusive KOL engagement
One of India’s most revered KOLs spoke on ‘Managing osteoporosis: challenges &
Garnered highest engagement & popularity on the platform
Consistently engage & respond to HCPs
Effective engagement through customized & standard responses to HCPs comments made on the platform
UPTICK IN PRESCRIPTION & SALE
for the three brands within 9 months
for both primary & secondary target
audiences, across metros & non metros
supporting the sales team in their covered
accounts and helping with consistent
messaging in non covered accounts &